Sanofi in Consumer Health

Company Profile

About This Report

Oct 2019

Sanofi remains the number four company in consumer health, with most of its recent growth originating from brands acquired from the asset swap with Boehringer Ingelheim in 2017. It has a strong yet varied portfolio, especially showing strength in Latin America, where it is the top consumer health company. As well as this, it continues to develop its digital health assets thereby futureproofing its business.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Sanofi in Consumer Health

Euromonitor International's report on Sanofi delivers a detailed strategic analysis of the company's business, examining its performance in the Vitamins and Dietary Supplements market and the global economy.

Company and market share data provide a detailed look at the financial position of Sanofi, while in-depth qualitative analysis will help you understand the brand strategy and growth prospects of Sanofi.

This report examines:
  • Company share by region and sector
  • Brand portfolio
  • New product developments
  • Marketing and distribution strategies

A detailed SWOT analysis of Sanofi provides strategic intelligence on:
  • Strengths and weaknesses
  • Category and country opportunities for growth
  • Challenges and threats from current competition and future prospects
  • Global and regional market positions

Research You Can Trust:

Euromonitor International's company profile reports are written by our Vitamins and Dietary Supplements research team, a dedicated group of analysts that knows the industry inside and out.

Buy this report to inform your planning, strategy, marketing, sales and competitor intelligence functions.

Delivery format

Reports are delivered in PDF format and can be downloaded from your online account immediately after purchase.

Introduction

Scope
Executive summary

State of Play

Top companies at a glance
Sanofi’s global footprint
Company overview
Sanofi’s growth is still driven by the BI asset swap

Exposure to Future Growth

Analgesics in Brazil and the US are key future growth markets for Sanofi

Competitive Positioning

Sanofi maintains shares while competitors are losing theirs
GSK see’s greater competitive overlap with Sanofi through Pfizer deal
All top 10 countries have shares in at least four out of the top five categories
Algerian health goods market set to grow
Sanofi’s Allegra/ Telfast and Dulcolax are not present in all key markets

OTC

Asia Pacific is a large global market yet a small region for Sanofi
Sanofi’s analgesics portfolio varies across Western Europe
Cough, cold and allergy is key growth area across most regions

Vitamins and Dietary Supplements

Eastern Europe provides strongest growth in VDS for Sanofi
Dietary supplements dominates all top markets but Japan
Brazil set to benefit most from Sanofi’s strong dietary supplements brands
Sanofi further its focus on digital health

Key Findings

Executive summary

Appendix

Projected company sales: FAQs (1)
Projected company sales: FAQs (2)